Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients with moderate to severe plaque psoriasis: Pooled results from three multicenter, randomized, double-blinded phase 3 trials
Authors: Kenneth B. Gordon, Michael Sebastian, Steven R. Feldman, Paolo Eusebi, Krista Wixted, Cynthia Madden, Natalie Nunez Gomez, Valerie Ciaravino, Marc Radtke
POSTER 49
< PREVIOUS POSTER NEXT POSTER >